PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy

Marks LS, Fradet Y, Deras IL, Blase A, Mathis J, Aubin SMJ, Cancio AT, Desaulniers M, Ellis WJ, Rittenhouse H, Groskopf J.
Urology 2007;69:532-5

• This study in 233 men with ≥ 1 negative biopsy demonstrates the clinical utility of the PCA3 Score in guiding decision which men need repeat biopsy.
• In total, 27% of men had a positive repeat biopsy.
• The repeat biopsy rate increased with higher PCA3 Scores (Figure).
• A PCA3 Score of 35 provided the greatest diagnostic accuracy, i.e. balance between sensitivity (58%) and specificity (72%).
• Men with a PCA3 Score < 35 had a decreased likelihood of a positive biopsy (17%); men with a PCA3 Score ≥ 35 a 2.5-fold increased likelihood (43%).

Reviewed by

Prof. J. Schalken, Prof. B. Tombal, Prof. H. Van Poppel

More information: http://www.ncbi.nlm.nih.gov/